adriandino
2021-08-26
Good
Pfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":810201389,"tweetId":"810201389","gmtCreate":1629977438641,"gmtModify":1633681075879,"author":{"id":3557838603033373,"idStr":"3557838603033373","authorId":3557838603033373,"authorIdStr":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/810201389","repostId":1171909968,"repostType":4,"repost":{"id":"1171909968","kind":"news","pubTimestamp":1629976999,"share":"https://ttm.financial/m/news/1171909968?lang=&edition=full","pubTime":"2021-08-26 19:23","market":"us","language":"en","title":"Pfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=1171909968","media":"The Wall Street Journal","summary":"Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution ","content":"<p>Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/565070b459fcd837a5c43c1b4a738fa9\" tg-width=\"860\" tg-height=\"573\" width=\"100%\" height=\"auto\"><span>Eurofarma will perform a manufacturing step known as fill-finish for the Pfizer-BioNTech vaccine.</span></p>\n<p>PfizerInc. and BioNTech SE said they are partnering with a Brazilian pharmaceutical company to help manufacture their Covid-19 vaccine in Latin America, which could help meet growing demand for the shot in the region.</p>\n<p>Eurofarma will produce at least 100 million doses annually for distribution in the region, Pfizer and BioNTech said Thursday.</p>\n<p>The doses will be in addition to those reaching Latin America through distribution channels such as Covax, the global initiative intended to get vaccines to low-income countries, and donations by the U.S., the companies said.</p>\n<p>Pfizer and BioNTech said manufacturing will begin next year, after the companies have completed a lengthy process known as technology transfer, in which they provide Eurofarma with top-secret information about the vaccine, manufacturing know-how and other key details.</p>\n<p>The Eurofarma deal is the first in Latin America for the shot from Pfizer and BioNTech, which along with other vaccine makers have been under pressure to increase supply for poorer countries. South Africa and other countries with tight supplies have proposed temporarily waiving patent protections so they can make the shots. Vaccine makers have opposed the measure, saying a technology transfer is a long and complex process and there is limited capacity.</p>\n<p>“We will continue to explore and pursue opportunities such as this to help ensure that vaccines are available to all who are in need,” said Pfizer Chief Executive Albert Bourla.</p>\n<p>Latin America is slowly overcoming vaccine-supply problems, and vaccinations have risen sharply.</p>\n<p>Supply concerns could be renewed, though, should more countries prepare to administer booster shots to maintain protection against the virus. The U.S. last week recommended additional shots for adults starting next month for people vaccinated from messenger RNA vaccines such as Pfizer’s.</p>\n<p>Latin America, home to about 8% of the world’s population, accounts for roughly a third of global deaths from the pandemic, according to Johns Hopkins University.</p>\n<p>The Pfizer-BioNTech vaccine involves a new gene-based technology called mRNA. Health authorities have confronted limited supplies as companies increase manufacturing. Some of the steps have been tough to scale up quickly, in part because they haven’t been performed before, according to manufacturing experts and the companies.</p>\n<p>Eurofarma, based in São Paulo, will receive drug products from the U.S. and then perform a standard manufacturing step known as fill-finish, in which vials are filled with vaccines, capped and readied for shipment.</p>\n<p>“At such a difficult time as this one, being able to share this news fills us with pride and hope,” said Eurofarma President Maurizio Billi.</p>\n<p>Pfizer and BioNTech say they have shipped more than 1.3 billion doses to more than 120 countries and territories around the world. The companies say they can produce about three billion doses this year and four billion next year.</p>\n<p>Other vaccine makers, including Moderna Inc. and AstraZeneca PLC, have alsoturned to outside manufacturersto increase production.</p>\n<p>Pfizer and BioNTech have struck manufacturing partnerships with rival drugmakers such asNovartisAGas well as other companies such as Thermo Fisher Scientific Inc.Pfizer and BioNTech said the manufacturing network for the vaccine now spans four continents and more than 20 plants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 19:23 GMT+8 <a href=https://www.wsj.com/articles/pfizer-biontech-expand-covid-19-vaccine-manufacturing-into-latin-america-11629974701?mod=hp_lead_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region\nEurofarma will perform a manufacturing step known as fill-finish for the Pfizer-...</p>\n\n<a href=\"https://www.wsj.com/articles/pfizer-biontech-expand-covid-19-vaccine-manufacturing-into-latin-america-11629974701?mod=hp_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-biontech-expand-covid-19-vaccine-manufacturing-into-latin-america-11629974701?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171909968","content_text":"Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region\nEurofarma will perform a manufacturing step known as fill-finish for the Pfizer-BioNTech vaccine.\nPfizerInc. and BioNTech SE said they are partnering with a Brazilian pharmaceutical company to help manufacture their Covid-19 vaccine in Latin America, which could help meet growing demand for the shot in the region.\nEurofarma will produce at least 100 million doses annually for distribution in the region, Pfizer and BioNTech said Thursday.\nThe doses will be in addition to those reaching Latin America through distribution channels such as Covax, the global initiative intended to get vaccines to low-income countries, and donations by the U.S., the companies said.\nPfizer and BioNTech said manufacturing will begin next year, after the companies have completed a lengthy process known as technology transfer, in which they provide Eurofarma with top-secret information about the vaccine, manufacturing know-how and other key details.\nThe Eurofarma deal is the first in Latin America for the shot from Pfizer and BioNTech, which along with other vaccine makers have been under pressure to increase supply for poorer countries. South Africa and other countries with tight supplies have proposed temporarily waiving patent protections so they can make the shots. Vaccine makers have opposed the measure, saying a technology transfer is a long and complex process and there is limited capacity.\n“We will continue to explore and pursue opportunities such as this to help ensure that vaccines are available to all who are in need,” said Pfizer Chief Executive Albert Bourla.\nLatin America is slowly overcoming vaccine-supply problems, and vaccinations have risen sharply.\nSupply concerns could be renewed, though, should more countries prepare to administer booster shots to maintain protection against the virus. The U.S. last week recommended additional shots for adults starting next month for people vaccinated from messenger RNA vaccines such as Pfizer’s.\nLatin America, home to about 8% of the world’s population, accounts for roughly a third of global deaths from the pandemic, according to Johns Hopkins University.\nThe Pfizer-BioNTech vaccine involves a new gene-based technology called mRNA. Health authorities have confronted limited supplies as companies increase manufacturing. Some of the steps have been tough to scale up quickly, in part because they haven’t been performed before, according to manufacturing experts and the companies.\nEurofarma, based in São Paulo, will receive drug products from the U.S. and then perform a standard manufacturing step known as fill-finish, in which vials are filled with vaccines, capped and readied for shipment.\n“At such a difficult time as this one, being able to share this news fills us with pride and hope,” said Eurofarma President Maurizio Billi.\nPfizer and BioNTech say they have shipped more than 1.3 billion doses to more than 120 countries and territories around the world. The companies say they can produce about three billion doses this year and four billion next year.\nOther vaccine makers, including Moderna Inc. and AstraZeneca PLC, have alsoturned to outside manufacturersto increase production.\nPfizer and BioNTech have struck manufacturing partnerships with rival drugmakers such asNovartisAGas well as other companies such as Thermo Fisher Scientific Inc.Pfizer and BioNTech said the manufacturing network for the vaccine now spans four continents and more than 20 plants.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":311,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/810201389"}
精彩评论